Tag: physical sciences
-
Immune Disease Biotech Acquired in $405M Deal
A biotechnology developer of treatments for autoimmune disorders with checkpoint receptor proteins is acquired by drug maker Gilead Sciences.
-
Peptide Vaccine Shown to Reduce Harmful Cholesterol
Tests with lab monkeys show a vaccine with a synthetic peptide lowers so-called bad cholesterol in blood for longer periods than a comparable monoclonal antibody.
-
Biotech Start-Up Demonstrates Cancer Therapy, Raises $6.4M
A new biotechnology company demonstrated in lab mice its therapy for glioblastoma, an aggressive brain cancer, that overcomes limitations of current treatments.
-
Ginkgo Acquires Biomaterials Maker as Industry Consolidates
A developer of synthetic biology tools and components is acquiring a biological materials developer for its automation assets as the biotechnology industry consolidates.
-
Infographic – Digital Health Keeps Clicking in 2022
While venture capital funding for digital health start-ups worldwide is down compared to last year, the pace so far in 2022 remains on an historically strong track.
-
AI System Shown to Provide Early Sepsis Warnings
A system using machine learning algorithms is shown to provide early warnings about sepsis developing in hospitalized patients, reducing injury and death.
-
Trial Okayed for Engineered Cell Cancer Therapy
A clinical trial is set to begin testing engineered immune-system cells designed to precisely target and infiltrate cancerous tumors without other potentially toxic proteins.
-
Surgical Robotics Company Raises $55M in Early Funds
A developer of robotic systems for cataract and other eye surgeries is raising $55 million in its first venture financing round.
-
NIH Funding Engineered Phage Screening Device
National Institutes of Health is funding initial development of a microfluidic device that tests engineered viruses for their ability to kill disease-causing bacteria.
-
Precision Protein Design Start-Up Gains $40M in Early Funds
A start-up company designing and testing precise proteins within live animals to speed creation of new therapeutics is raising $40 million in its first venture round.